Capillary Blood Collection Devices Market Projected To Grow At A CAGR Of 6.64% During The Forecast Period 2020 To 2025

Increasing prevalence of infectious and non-communicable diseases, the mounting number of accidents and trauma is anticipated to boost the Capillary Blood Collection Devices market during the forecast period 2020-2025. Capillary Blood Collection Devices Market size is $1410.60m in 2019, growing at a CAGR of 6.64% during the forecast period 2020-2025.

The Capillary Blood Collection Devices market is growing at a significant rate as medical device manufacturers are making substantial improvements toward safer blood collection products. They have emphasized the prevention of injury and reduction of blood borne pathogen exposure. Capillary Blood Collection Devices is used for glucose measurements by transferring the blood to a test strip and it provides information regarding the capillary blood collection at home. Diabetics routinely check their blood sugars this way. Capillary Blood facilitates collection devices that enable rapid hematology tests with the aid of Poc diagnostics.

Recent advancements in capillary blood collection systems such as blood drawn by venipuncture, pivo device, micro sampling technology, and so on are set to drive the adoption of capillary blood collection devices in the medical industry. Micro sampling technology enables the collection of very tiny amounts of blood that are enough to evaluate the biochemistry parameters of blood with an accurate and precise collection of a fixed volume of blood while eliminating bias posed by dried blood spotting hematocrit analysis. Makers of new blood collection devices are rethinking needles and venipuncture and opening an exciting frontier of capillary blood collection product design that can replace traditional venipunctures at medical laboratories and can collect 150 microliters of blood, enough to test for cholesterol, blood sugar, cancer cells, infections, and other ailments. Recently, Neoteryx developed a micro sampling based CE marked product Mitra which reduces the issues of hematocrit bias, in which level of hematocrit influence viscosity which in turn determines the actual volume of blood samples in a punch from the dried blood spot and it is compatible with standard high throughout lab instrumentation.

North America dominated the global market share of capillary blood collection devices in 2019 owing to the increasing number of surgical procedures, mounting cases of accidents, and increasing prevalence of non-communicable diseases such as cancer, cardiovascular disorder, chronic respiratory disorders, and diabetes. The growing trend towards innovations in blood collection is owing to the diagnostic test results that inform upwards 70-80 percent of clinical decisions. Two firms won US Food and Drug Administration 510(k) clearances for blood collection devices recently, a push-button device from Seventh Sense called TAP and a needle-free device from Velano Vascular, called Pivo. Meanwhile, other firms, like Neoteryx, are pursuing micro sampling of blood but that specializes in dried blood spots. The recent Food and Drug Administration(FDA) clearance was for the second generation of Pivo, which was enhanced for manufacturability and usability based on customer feedback and is also developing new, as-yet-undisclosed products to improve efficiency and provide more human care for hospitalized patients. GE Ventures has announced the launch of Drawbridge Health, a private diagnostic testing startup developing proprietary technology designed to integrate blood draw, collection, and sample stabilization into one device. Healthcare providers using the new blood collection technology are going to be ready to deliver a superior patient experience. This integrated technology is additionally being developed to support temperature shipping and streamlined downstream processing, ensuring reliable, accurate results. A large population base, improving healthcare infrastructure, growing medical tourism, increasing number of hospitals, and rising disposable incomes within the region are expected to supply significant growth opportunities for key players operating in the market. Regulatory agencies such as the Food and Drug Administration (FDA), International Organization for Standardization (ISO), and Clinical and Laboratory Standard Institutes (CLSI) enforce guidelines that ensure the blood collection systems are consistent in both design and manufacture. All these factors are set to avail new growth opportunities to capillary blood collection devices market in the region during 2020-2025.

Non-communicable diseases also termed as chronic diseases are collectively responsible for 71% of all deaths worldwide. Almost three-quarters of all non-communicable death and 82% of the 16 million died prematurely or before reaching 70 years. Non-communicable diseases are identified by WHO as “Group II diseases”. Capillary blood collection devices are set to dominate the future landscape, particularly for non-communicable diseases and other diseases that have been proven intractable with current blood collection devices. Major investments on capillary blood collection devices explore unique applications for diagnostics and therapeutics purposes and have enabled the collection of a very tiny amount of blood that is enough to evaluate the drug levels and the biochemistry parameters of the blood.

Apart from non-communicable diseases, an increasing number of surgical procedures, mounting cases of accidents, and trauma cases is increasing the growth of the capillary blood collection devices market. Hence, the discovery and manufacture of capillary blood collection devices hold promise for developing effective treatment procedures for non-communicable diseases.

Micro sampling technology has enabled the collection of very tiny amounts of blood that are enough to evaluate the drug levels and the biochemistry parameters of the blood. It also enables accurate and precise collection of a fixed volume of blood while eliminating bias posed by dried blood spotting hematocrit analysis that is volumetric blood hematocrit which is easier to use and helps in the collection of blood from remote locations. Moreover, the blood collected does not require cold storage or biohazard transportation, consequently eliminating associated costs. The micro samples are available in several formats, including the clamshell and the cartridge. The cartridge format is a suitable device for remote blood collection. It uses native barcoding and its associated accessories include a resealable bag. This is set to give a boost in the capillary blood collection devices market in upcoming years.

Thermo Fisher Scientific Inc. which is an American provisioner of software and services to healthcare, life science, and other laboratories acquired $392 million of the laboratory products and services segment of the company Alfa Aesar with an aim to expand the company’s existing portfolio of the chemical solvents.

In February 2018, DBS System has launched its HemaXis DB micro blood collection device in the United States with a Food and Drug Administration class 1 medical device listing.HemaXis  DB is DBS System’s first-generation device for the collection, transport, and storage of capillary whole blood sample.

The major companies in the Capillary Blood Collection Devices market include B. Braun Melsungen Ag,  Abbott Laboratories, Cardinal Health, Greiner Bio-One International Gmbh, Kabe Labortechnik Gmbh, Nipro Nv, Owen Mumford Ltd, Sarstedt Ag Co. Kg, Terumo Medical Group, Thermo Fisher Scientific Inc., and others. In December 2017, B.Braun Melsungen Ag established a subsidiary in Zambia and In January 2017, Abbott Laboratories acquired St.Jude Medical to strengthen its medical device leadership with innovations and neuromodulation.

Over the years, major market players have focused on needle and syringes which were typically used for collection, and the blood was transferred to the non-sterile tubes for transport to the laboratory. Launch of new market companies, adequate funding, and government-aided policies helps in the development of Capillary Blood Collection Devices. The continuous developments in the Capillary Blood Collection Devices Market such as the adoption of micro sampling technology, DBS Cards, POC diagnostics, advanced technologies, increasing funding amount of startups and research organizations and surge in the number of product and blood collection devices approvals by Food and Drug Administration(FDA) are the major factors set to drive the Capillary Blood Collection Devices market during the forecast period 2020-2025.